![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: UGCG |
Gene summary for UGCG |
![]() |
Gene information | Species | Human | Gene symbol | UGCG | Gene ID | 7357 |
Gene name | UDP-glucose ceramide glucosyltransferase | |
Gene Alias | GCS | |
Cytomap | 9q31.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A024R157 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7357 | UGCG | PTC01 | Human | Thyroid | PTC | 3.70e-09 | 8.81e-02 | 0.1899 |
7357 | UGCG | PTC04 | Human | Thyroid | PTC | 2.05e-12 | 1.44e-01 | 0.1927 |
7357 | UGCG | PTC05 | Human | Thyroid | PTC | 6.91e-08 | 4.45e-01 | 0.2065 |
7357 | UGCG | PTC06 | Human | Thyroid | PTC | 1.87e-14 | 4.03e-01 | 0.2057 |
7357 | UGCG | PTC07 | Human | Thyroid | PTC | 5.23e-20 | 3.54e-01 | 0.2044 |
7357 | UGCG | ATC09 | Human | Thyroid | ATC | 5.58e-30 | 1.45e+00 | 0.2871 |
7357 | UGCG | ATC12 | Human | Thyroid | ATC | 1.06e-31 | 7.68e-01 | 0.34 |
7357 | UGCG | ATC13 | Human | Thyroid | ATC | 7.88e-27 | 3.87e-01 | 0.34 |
7357 | UGCG | ATC1 | Human | Thyroid | ATC | 9.40e-26 | 1.50e+00 | 0.2878 |
7357 | UGCG | ATC2 | Human | Thyroid | ATC | 8.12e-17 | 1.41e+00 | 0.34 |
7357 | UGCG | ATC3 | Human | Thyroid | ATC | 1.78e-11 | 1.13e+00 | 0.338 |
7357 | UGCG | ATC4 | Human | Thyroid | ATC | 2.37e-37 | 1.04e+00 | 0.34 |
7357 | UGCG | ATC5 | Human | Thyroid | ATC | 9.18e-25 | 4.24e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
GO:00302164 | Cervix | CC | keratinocyte differentiation | 42/2311 | 139/18723 | 1.74e-08 | 1.28e-06 | 42 |
GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
GO:005087810 | Cervix | CC | regulation of body fluid levels | 78/2311 | 379/18723 | 3.20e-06 | 8.77e-05 | 78 |
GO:00192213 | Cervix | CC | cytokine-mediated signaling pathway | 84/2311 | 472/18723 | 3.25e-04 | 3.44e-03 | 84 |
GO:00614362 | Cervix | CC | establishment of skin barrier | 10/2311 | 25/18723 | 4.52e-04 | 4.49e-03 | 10 |
GO:00335612 | Cervix | CC | regulation of water loss via skin | 10/2311 | 27/18723 | 9.25e-04 | 7.84e-03 | 10 |
GO:00070092 | Cervix | CC | plasma membrane organization | 28/2311 | 142/18723 | 7.85e-03 | 4.14e-02 | 28 |
GO:005087815 | Endometrium | AEH | regulation of body fluid levels | 64/2100 | 379/18723 | 5.40e-04 | 5.44e-03 | 64 |
GO:00435885 | Endometrium | AEH | skin development | 45/2100 | 263/18723 | 2.58e-03 | 1.90e-02 | 45 |
GO:00085447 | Endometrium | AEH | epidermis development | 52/2100 | 324/18723 | 5.00e-03 | 3.14e-02 | 52 |
GO:00717096 | Endometrium | AEH | membrane assembly | 12/2100 | 50/18723 | 8.00e-03 | 4.43e-02 | 12 |
GO:005087816 | Endometrium | EEC | regulation of body fluid levels | 65/2168 | 379/18723 | 7.48e-04 | 7.05e-03 | 65 |
GO:004358814 | Endometrium | EEC | skin development | 45/2168 | 263/18723 | 4.69e-03 | 2.99e-02 | 45 |
GO:000854414 | Endometrium | EEC | epidermis development | 53/2168 | 324/18723 | 5.92e-03 | 3.54e-02 | 53 |
GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
GO:00464673 | Esophagus | ESCC | membrane lipid biosynthetic process | 91/8552 | 142/18723 | 7.19e-06 | 7.19e-05 | 91 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa006003 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa0060012 | Esophagus | ESCC | Sphingolipid metabolism | 36/4205 | 53/8465 | 5.41e-03 | 1.36e-02 | 6.99e-03 | 36 |
hsa00600 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa006001 | Liver | HCC | Sphingolipid metabolism | 34/4020 | 53/8465 | 1.06e-02 | 2.71e-02 | 1.51e-02 | 34 |
hsa006002 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
hsa0060011 | Oral cavity | OSCC | Sphingolipid metabolism | 33/3704 | 53/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 33 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UGCG | SNV | Missense_Mutation | c.706N>C | p.Asp236His | p.D236H | Q16739 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
UGCG | SNV | Missense_Mutation | novel | c.769N>C | p.Ala257Pro | p.A257P | Q16739 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | c.187N>T | p.Asp63Tyr | p.D63Y | Q16739 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
UGCG | SNV | Missense_Mutation | novel | c.272N>C | p.Asp91Ala | p.D91A | Q16739 | protein_coding | tolerated(0.29) | benign(0.218) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | novel | c.226N>A | p.Leu76Met | p.L76M | Q16739 | protein_coding | tolerated(0.71) | benign(0.209) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UGCG | SNV | Missense_Mutation | novel | c.268C>A | p.His90Asn | p.H90N | Q16739 | protein_coding | tolerated(0.24) | benign(0) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
UGCG | SNV | Missense_Mutation | c.767T>C | p.Val256Ala | p.V256A | Q16739 | protein_coding | tolerated(0.4) | possibly_damaging(0.447) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
UGCG | SNV | Missense_Mutation | novel | c.79T>G | p.Phe27Val | p.F27V | Q16739 | protein_coding | tolerated(0.31) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
UGCG | SNV | Missense_Mutation | c.800N>A | p.Ser267Tyr | p.S267Y | Q16739 | protein_coding | tolerated(0.05) | benign(0.011) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
UGCG | SNV | Missense_Mutation | novel | c.109N>A | p.Leu37Ile | p.L37I | Q16739 | protein_coding | deleterious(0.01) | possibly_damaging(0.854) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Eliglustat tartrate | |||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL2103853 | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1029 | MIGLUSTAT | |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | MIGLUSTAT | MIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | ADRIAMYCIN | ADRIAMYCIN | 10702281 | |
7357 | UGCG | ENZYME, DRUGGABLE GENOME | ELIGLUSTAT | ELIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Miglustat | MIGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | GZ402671 | VENGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Venglustat | VENGLUSTAT | ||
7357 | UGCG | ENZYME, DRUGGABLE GENOME | Genz-682452 | VENGLUSTAT |
Page: 1 2 |